Literature DB >> 17430708

Tuberculosis, drug resistance, and HIV/AIDS: a triple threat.

Gerald Friedland1.   

Abstract

The worldwide epidemics of tuberculosis (TB) and HIV/AIDS have been joined by an insidiously developing third epidemic of TB drug resistance. Fueled by the disruption of TB control programs and the explosive growth of HIV/AIDS, the presence of TB drug resistance, particularly multiple drug resistance, is worldwide and threatens the gains made in the past decades in the treatment of both TB and HIV. Although treatment success is possible, the diagnosis and treatment of drug-resistant TB is difficult. Advances in TB diagnosis and treatment have been minimal in the past 40 years, and there is an urgent need for wider distribution of available diagnostic technology and for the development and testing of newer rapid molecular diagnostic techniques and therapeutic agents. This review discusses current information about the distribution of multiple drug-resistant and newer extensively drug-resistant TB as well as available diagnostic and therapeutic strategies with an emphasis on the relationship between TB drug resistance and HIV/AIDS.

Entities:  

Year:  2007        PMID： 17430708     DOI： 10.1007/s11908-007-0039-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  26 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

Review 2.  Programmes and principles in treatment of multidrug-resistant tuberculosis.

Authors:  Joia S Mukherjee; Michael L Rich; Adrienne R Socci; J Keith Joseph; Felix Alcántara Virú; Sonya S Shin; Jennifer J Furin; Mercedes C Becerra; Donna J Barry; Jim Yong Kim; Jaime Bayona; Paul Farmer; Mary C Smith Fawzi; Kwonjune J Seung
Journal:  Lancet       Date:  2004-02-07       Impact factor: 79.321

3.  Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002.

Authors:  L J Nelson; E A Talbot; M J Mwasekaga; P K Ngirubiu; R A Mwansa; M Notha; C D Wells
Journal:  Lancet       Date:  2005 Aug 6-12       Impact factor: 79.321

4.  Partnering for better microbial diagnostics.

Authors:  Mark D Perkins; Peter M Small
Journal:  Nat Biotechnol       Date:  2006-08       Impact factor: 54.908

5.  Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

Authors:  Gillian L Dean; Simon G Edwards; Natalie J Ives; Gail Matthews; Emma F Fox; Lesley Navaratne; Martin Fisher; Graham P Taylor; Rob Miller; Chris B Taylor; Annemiek de Ruiter; Anton L Pozniak
Journal:  AIDS       Date:  2002-01-04       Impact factor: 4.177

6.  Tuberculosis control in resource-poor countries: alternative approaches in the era of HIV.

Authors:  K M De Cock; D Wilkinson
Journal:  Lancet       Date:  1995-09-09       Impact factor: 79.321

7.  Patterns of anti-tuberculosis drug resistance among HIV-infected patients in Maputo, Mozambique, 2002-2003.

Authors:  E A Nunes; E M De Capitani; E Coelho; O A Joaquim; I R O Figueiredo; A M Cossa; A C Panunto; M Carvalho-Ramos
Journal:  Int J Tuberc Lung Dis       Date:  2005-05       Impact factor: 2.373

8.  Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

Authors:  Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

9.  Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries.

Authors:  Gerald Friedland; Salim Abdool Karim; Quarraisha Abdool Karim; Umesh Lalloo; Christopher Jack; Neel Gandhi; Wafaa El Sadr
Journal:  Clin Infect Dis       Date:  2004-06-01       Impact factor: 9.079

10.  Multidrug-resistant tuberculosis management in resource-limited settings.

Authors:  Eva Nathanson; Catharina Lambregts-van Weezenbeek; Michael L Rich; Rajesh Gupta; Jaime Bayona; Kai Blöndal; José A Caminero; J Peter Cegielski; Manfred Danilovits; Marcos A Espinal; Vahur Hollo; Ernesto Jaramillo; Vaira Leimane; Carole D Mitnick; Joia S Mukherjee; Paul Nunn; Alexander Pasechnikov; Thelma Tupasi; Charles Wells; Mario C Raviglione
Journal:  Emerg Infect Dis       Date:  2006-09       Impact factor: 6.883
View more
  12 in total

1.  Association of strong immune responses to PPE protein Rv1168c with active tuberculosis.

Authors:  Nooruddin Khan; Kaiser Alam; Shiny Nair; Vijaya Lakshmi Valluri; Kolluri J R Murthy; Sangita Mukhopadhyay
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

2.  Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.

Authors:  Gerald Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

Review 3.  Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Authors:  Katherine A Sacksteder; Marina Protopopova; Clifton E Barry; Koen Andries; Carol A Nacy
Journal:  Future Microbiol       Date:  2012-07       Impact factor: 3.165

4.  Treatment Outcomes of Children With HIV Infection and Drug-resistant TB in Three Provinces in South Africa, 2005-2008.

Authors:  Eric W Hall; Sapna B Morris; Brittany K Moore; Linda Erasmus; Ronel Odendaal; Heather Menzies; Martie van der Walt; Sarah E Smith
Journal:  Pediatr Infect Dis J       Date:  2017-12       Impact factor: 2.129

Review 5.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

Review 6.  Managing tuberculosis and HIV in sub-Sahara Africa.

Authors:  Umesh G Lalloo; Sandy Pillay
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

Review 7.  Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community.

Authors:  Sheela Shenoi; Scott Heysell; Anthony Moll; Gerald Friedland
Journal:  Curr Opin Infect Dis       Date:  2009-02       Impact factor: 4.915

Review 8.  Extensively drug-resistant tuberculosis: a new face to an old pathogen.

Authors:  Sheela Shenoi; Gerald Friedland
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

9.  Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis.

Authors:  Diane Ordway; Marcela Henao-Tamayo; Crystal Shanley; Erin E Smith; Gopinath Palanisamy; Baolin Wang; Randall J Basaraba; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2008-05-28

10.  Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti.

Authors:  Macarthur Charles; Stalz Charles Vilbrun; Serena P Koenig; Lauren M Hashiguchi; Marie Marcelle Mabou; Oksana Ocheretina; Jean W Pape
Journal:  Am J Trop Med Hyg       Date:  2014-07-28       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.